论文部分内容阅读
目的：分析癌基因 mdm- 2和抑癌基因 p53在胃癌及其转移灶中的变异及相互关系，探讨胃癌及其转移的分子机制。 方法：采用 DC- PCR、 PCR- SSCP及 DNA测序技术检测 32例胃癌及其转移灶中的 mdm- 2扩增和 p53突变。结果： mdm- 2在转移淋巴结中的扩增频率（ 12/21， 57.1％）高于胃原发癌灶（ 12/32， 37.5％）， 3例淋巴微转移灶中出现 mdm- 2的扩增。在 7例肠型胃癌的原发癌或转移癌灶中同时检测出 mdm- 2扩增和 p53突变。肝转移癌灶中 p53突变位点和突变方式与胃原发癌之间有差异。结论： mdm- 2扩增可能与胃癌细胞的淋巴高转移潜能有关。 p53突变和 mdm- 2扩增多并存于肠型胃癌中。在胃原发癌和肝转移癌中癌细胞的基因改变存在着异质性。
Objective: To analyze the variation and relationship of oncogene mdm-2 and tumor suppressor gene p53 in gastric cancer and its metastases, and to explore the molecular mechanism of gastric cancer and its metastasis. Methods: DC-PCR, PCR-SSCP and DNA sequencing were used to detect mdm-2 amplification and p53 mutation in 32 cases of gastric cancer and its metastases. RESULTS: The amplification frequency of mdm-2 in metastatic lymph nodes (12/21, 57.1%) was higher than that in primary gastric cancer (12/32, 37.5%), and mdm-2 was seen in 3 cases of lymph node micrometastases. increase. Mdm-2 amplification and p53 mutations were detected in the primary or metastatic lesions of 7 cases of intestinal type gastric cancer. There were differences between p53 mutation sites and mutation patterns and primary gastric cancer in liver metastases. Conclusion: The amplification of mdm-2 may be related to the lymphatic metastasis potential of gastric cancer cells. Mutation of p53 and mdm-2 are mostly coexist in intestinal type gastric cancer. There is heterogeneity in the genetic alteration of cancer cells in primary gastric cancer and hepatic metastatic cancer.